Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial
Indian Journal of Pharmacology · 2025
DOI: 10.4103/ijp.ijp_824_25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Pharmacology, 2025. Verfasst von Aman Agrawal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, PGIMER, Chandigarh, India. Hauptthemen laut MEDLINE: Tranexamic Acid, Hemoptysis, Antifibrinolytic Agents. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
OBJECTIVES: The objective of this study was to evaluate the efficacy and safety of tranexamic acid (TXA) nebulization to control bleeding in hemoptysis. MATERIALS AND METHODS: In this randomized controlled clinical trial, 27 participants with hemoptysis received nebulization with TXA (500 mg/5 mL, q 8 hourly for 2 days), and 29 participants with hemoptysis received nebulization with 0.9% normal saline (5 mL, q 8 hourly for 2 days) along with the standard therapy and followed up for 8 weeks. RESULTS: The mean percentage decrease in the frequency (63.9% vs. 39.8%, P = 0.012) and quantity (73.4% vs. 51.7%, P = 0.024) of hemoptysis was significantly higher in the TXA group compared to the control group at day 1 but was insignificant at day 2. However, after excluding participants who underwent intervention ( N = 11), the improvement in frequency (76.2% vs. 50.3%, P = 0.049) and quantity (85.2% vs. 58.6%, P = 0.021) of hemoptysis was significantly better in the TXA group even at day 2. Out of 56 participants, 24 participants achieved resolution of hemoptysis, which was also significantly ( P = 0.003) better in the TXA group (63.0%) compared to the control group (24.1%). No serious adverse drug reaction was observed. Minor cough (37.5%) and throat irritation (33.9%) were observed, which were comparable ( P = 0.432) between the groups. CONCLUSION: TXA nebulization, an alternative route of administration, was found to be safe. Prompt nebulization with TXA was effective as bridging therapy in hemoptysis to achieve the immediate goal of bleeding control before definitive intervention planned or performed. Further studies are encouraged to evaluate this novel approach of TXA nebulization. Trial registration: clinicaltrials.gov PRS ID: NCT05648656.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, PGIMER, Chandigarh, India.
- Department of Pharmacology, PGIMER, Chandigarh, India.
- Department of Radio Diagnosis and Imaging, PGIMER, Chandigarh, India.
- Department Pulmonary Medicine, PGIMER, Chandigarh, India.
Zitieren
APA
Agrawal, A., Dhibar, D. P., Prakash, A., Sreedhara, B. C., Muthu, V., & Pannu, A. K. (2025). Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_824_25
Vancouver
Agrawal A, Dhibar DP, Prakash A, Sreedhara BC, Muthu V, Pannu AK. Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial. Indian Journal of Pharmacology. 2025. doi:10.4103/ijp.ijp_824_25
BibTeX
@article{Agrawal2025,
author = {Agrawal, Aman and Dhibar, Deba Prasad and Prakash, Ajay and Sreedhara, B C and Muthu, Valliappan and Pannu, Ashok Kumar},
title = {Efficacy and safety of tranexamic acid nebulization to control bleeding of hemoptysis: The TXA-NEB randomized controlled clinical trial},
journal = {Indian Journal of Pharmacology},
year = {2025},
doi = {10.4103/ijp.ijp_824_25}
}
EUVIMED